v3.26.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended September 30, 2026:

Name and Title

 

Type of Trading Arrangement

 

Action Taken
(Date of Action)

 

Duration or End Date

 

Aggregate Number of Securities to be Sold

 

Description of Trading Arrangement

William Savage, M.D., Ph.D.
Chief Medical Officer

 

Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c)

 

Adoption
(September 15, 2026)

 

End Date
(March 19, 2027)

 

Up to 23,8861

 

Sale

 

 

 

 

 

 

 

 

 

 

 

(1) The aggregate number of shares available for sale cannot yet be determined, as it will be reduced by the number of shares sold to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs). For disclosure purposes, the figures in this table reflect the maximum number of shares underlying the RSUs, without deducting shares that may be sold to cover taxes.
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Rule 10b5-1 Arrangement Modified false
Non-Rule 10b5-1 Arrangement Modified false
William Savage [Member]  
Trading Arrangements, by Individual  
Name William Savage
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 15, 2026
Expiration Date March 19, 2027
Arrangement Duration 185 days
Aggregate Available 23,886